nodes	percent_of_prediction	percent_of_DWPC	metapath
Buprenorphine—ABCG2—Teniposide—lymphatic system cancer	0.119	0.15	CbGbCtD
Buprenorphine—ABCG2—Mitoxantrone—lymphatic system cancer	0.0833	0.105	CbGbCtD
Buprenorphine—CYP1A2—Carmustine—lymphatic system cancer	0.0731	0.0922	CbGbCtD
Buprenorphine—CYP3A5—Teniposide—lymphatic system cancer	0.066	0.0832	CbGbCtD
Buprenorphine—ABCG2—Vincristine—lymphatic system cancer	0.0573	0.0723	CbGbCtD
Buprenorphine—CYP2C19—Teniposide—lymphatic system cancer	0.0532	0.0671	CbGbCtD
Buprenorphine—CYP2C9—Teniposide—lymphatic system cancer	0.0443	0.0558	CbGbCtD
Buprenorphine—CYP3A7—Vincristine—lymphatic system cancer	0.0423	0.0534	CbGbCtD
Buprenorphine—CYP3A7-CYP3A51P—Vincristine—lymphatic system cancer	0.0423	0.0534	CbGbCtD
Buprenorphine—ABCG2—Methotrexate—lymphatic system cancer	0.0347	0.0438	CbGbCtD
Buprenorphine—CYP3A5—Vincristine—lymphatic system cancer	0.0318	0.0401	CbGbCtD
Buprenorphine—ABCB1—Mitoxantrone—lymphatic system cancer	0.03	0.0379	CbGbCtD
Buprenorphine—CYP3A4—Cytarabine—lymphatic system cancer	0.0261	0.0329	CbGbCtD
Buprenorphine—CYP3A4—Teniposide—lymphatic system cancer	0.0257	0.0325	CbGbCtD
Buprenorphine—ABCB1—Vincristine—lymphatic system cancer	0.0207	0.0261	CbGbCtD
Buprenorphine—CYP3A4—Mitoxantrone—lymphatic system cancer	0.018	0.0227	CbGbCtD
Buprenorphine—ABCB1—Methotrexate—lymphatic system cancer	0.0125	0.0158	CbGbCtD
Buprenorphine—CYP3A4—Vincristine—lymphatic system cancer	0.0124	0.0156	CbGbCtD
Buprenorphine—Rhinitis—Mitoxantrone—lymphatic system cancer	0.000467	0.00225	CcSEcCtD
Buprenorphine—Hypersensitivity—Teniposide—lymphatic system cancer	0.000466	0.00225	CcSEcCtD
Buprenorphine—Flushing—Carmustine—lymphatic system cancer	0.000465	0.00224	CcSEcCtD
Buprenorphine—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.000463	0.00224	CcSEcCtD
Buprenorphine—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.000462	0.00223	CcSEcCtD
Buprenorphine—Feeling abnormal—Fludarabine—lymphatic system cancer	0.000458	0.00221	CcSEcCtD
Buprenorphine—Asthenia—Teniposide—lymphatic system cancer	0.000454	0.00219	CcSEcCtD
Buprenorphine—Malaise—Bleomycin—lymphatic system cancer	0.00045	0.00217	CcSEcCtD
Buprenorphine—Pruritus—Teniposide—lymphatic system cancer	0.000447	0.00216	CcSEcCtD
Buprenorphine—Depressed level of consciousness—Methotrexate—lymphatic system cancer	0.000446	0.00215	CcSEcCtD
Buprenorphine—Cardiac disorder—Vincristine—lymphatic system cancer	0.000444	0.00214	CcSEcCtD
Buprenorphine—Body temperature increased—Fludarabine—lymphatic system cancer	0.000439	0.00212	CcSEcCtD
Buprenorphine—Mental disorder—Carmustine—lymphatic system cancer	0.000439	0.00212	CcSEcCtD
Buprenorphine—Erythema—Carmustine—lymphatic system cancer	0.000436	0.0021	CcSEcCtD
Buprenorphine—Malnutrition—Carmustine—lymphatic system cancer	0.000436	0.0021	CcSEcCtD
Buprenorphine—Cough—Bleomycin—lymphatic system cancer	0.000436	0.0021	CcSEcCtD
Buprenorphine—Angiopathy—Vincristine—lymphatic system cancer	0.000434	0.00209	CcSEcCtD
Buprenorphine—Diarrhoea—Teniposide—lymphatic system cancer	0.000433	0.00209	CcSEcCtD
Buprenorphine—Mediastinal disorder—Vincristine—lymphatic system cancer	0.000431	0.00208	CcSEcCtD
Buprenorphine—Chest pain—Bleomycin—lymphatic system cancer	0.000425	0.00205	CcSEcCtD
Buprenorphine—Myalgia—Bleomycin—lymphatic system cancer	0.000425	0.00205	CcSEcCtD
Buprenorphine—Coma—Methotrexate—lymphatic system cancer	0.000422	0.00204	CcSEcCtD
Buprenorphine—Back pain—Carmustine—lymphatic system cancer	0.000422	0.00204	CcSEcCtD
Buprenorphine—Discomfort—Bleomycin—lymphatic system cancer	0.00042	0.00203	CcSEcCtD
Buprenorphine—Mental disorder—Vincristine—lymphatic system cancer	0.000419	0.00202	CcSEcCtD
Buprenorphine—Chills—Mitoxantrone—lymphatic system cancer	0.000418	0.00202	CcSEcCtD
Buprenorphine—Confusional state—Bleomycin—lymphatic system cancer	0.000411	0.00198	CcSEcCtD
Buprenorphine—Vision blurred—Carmustine—lymphatic system cancer	0.000411	0.00198	CcSEcCtD
Buprenorphine—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00041	0.00198	CcSEcCtD
Buprenorphine—Tremor—Carmustine—lymphatic system cancer	0.000408	0.00197	CcSEcCtD
Buprenorphine—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.000408	0.00197	CcSEcCtD
Buprenorphine—Oedema—Bleomycin—lymphatic system cancer	0.000408	0.00197	CcSEcCtD
Buprenorphine—Erythema—Mitoxantrone—lymphatic system cancer	0.000405	0.00196	CcSEcCtD
Buprenorphine—Infection—Bleomycin—lymphatic system cancer	0.000405	0.00195	CcSEcCtD
Buprenorphine—Back pain—Vincristine—lymphatic system cancer	0.000402	0.00194	CcSEcCtD
Buprenorphine—Vomiting—Teniposide—lymphatic system cancer	0.000402	0.00194	CcSEcCtD
Buprenorphine—Agitation—Carmustine—lymphatic system cancer	0.000401	0.00193	CcSEcCtD
Buprenorphine—Asthenia—Fludarabine—lymphatic system cancer	0.000399	0.00192	CcSEcCtD
Buprenorphine—Rash—Teniposide—lymphatic system cancer	0.000399	0.00192	CcSEcCtD
Buprenorphine—Dermatitis—Teniposide—lymphatic system cancer	0.000398	0.00192	CcSEcCtD
Buprenorphine—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000397	0.00192	CcSEcCtD
Buprenorphine—Headache—Teniposide—lymphatic system cancer	0.000396	0.00191	CcSEcCtD
Buprenorphine—Pruritus—Fludarabine—lymphatic system cancer	0.000393	0.0019	CcSEcCtD
Buprenorphine—Back pain—Mitoxantrone—lymphatic system cancer	0.000392	0.00189	CcSEcCtD
Buprenorphine—Anorexia—Bleomycin—lymphatic system cancer	0.000388	0.00188	CcSEcCtD
Buprenorphine—Agitation—Vincristine—lymphatic system cancer	0.000382	0.00185	CcSEcCtD
Buprenorphine—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000382	0.00184	CcSEcCtD
Buprenorphine—Hypotension—Bleomycin—lymphatic system cancer	0.000381	0.00184	CcSEcCtD
Buprenorphine—Diarrhoea—Fludarabine—lymphatic system cancer	0.00038	0.00184	CcSEcCtD
Buprenorphine—Convulsion—Carmustine—lymphatic system cancer	0.000378	0.00182	CcSEcCtD
Buprenorphine—Hypertension—Carmustine—lymphatic system cancer	0.000376	0.00182	CcSEcCtD
Buprenorphine—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000376	0.00181	CcSEcCtD
Buprenorphine—Nausea—Teniposide—lymphatic system cancer	0.000376	0.00181	CcSEcCtD
Buprenorphine—Vertigo—Vincristine—lymphatic system cancer	0.000374	0.0018	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000371	0.00179	CcSEcCtD
Buprenorphine—Chest pain—Carmustine—lymphatic system cancer	0.000371	0.00179	CcSEcCtD
Buprenorphine—Myalgia—Carmustine—lymphatic system cancer	0.000371	0.00179	CcSEcCtD
Buprenorphine—Anxiety—Carmustine—lymphatic system cancer	0.00037	0.00178	CcSEcCtD
Buprenorphine—Paraesthesia—Bleomycin—lymphatic system cancer	0.000366	0.00177	CcSEcCtD
Buprenorphine—Malaise—Mitoxantrone—lymphatic system cancer	0.000365	0.00176	CcSEcCtD
Buprenorphine—Dyspnoea—Bleomycin—lymphatic system cancer	0.000363	0.00175	CcSEcCtD
Buprenorphine—Convulsion—Vincristine—lymphatic system cancer	0.000361	0.00174	CcSEcCtD
Buprenorphine—Hypertension—Vincristine—lymphatic system cancer	0.000359	0.00173	CcSEcCtD
Buprenorphine—Confusional state—Carmustine—lymphatic system cancer	0.000359	0.00173	CcSEcCtD
Buprenorphine—Oedema—Carmustine—lymphatic system cancer	0.000356	0.00172	CcSEcCtD
Buprenorphine—Decreased appetite—Bleomycin—lymphatic system cancer	0.000354	0.00171	CcSEcCtD
Buprenorphine—Myalgia—Vincristine—lymphatic system cancer	0.000354	0.00171	CcSEcCtD
Buprenorphine—Visual disturbance—Methotrexate—lymphatic system cancer	0.000354	0.00171	CcSEcCtD
Buprenorphine—Cough—Mitoxantrone—lymphatic system cancer	0.000354	0.00171	CcSEcCtD
Buprenorphine—Infection—Carmustine—lymphatic system cancer	0.000353	0.00171	CcSEcCtD
Buprenorphine—Vomiting—Fludarabine—lymphatic system cancer	0.000353	0.00171	CcSEcCtD
Buprenorphine—Convulsion—Mitoxantrone—lymphatic system cancer	0.000351	0.00169	CcSEcCtD
Buprenorphine—Rash—Fludarabine—lymphatic system cancer	0.00035	0.00169	CcSEcCtD
Buprenorphine—Dermatitis—Fludarabine—lymphatic system cancer	0.00035	0.00169	CcSEcCtD
Buprenorphine—Hypertension—Mitoxantrone—lymphatic system cancer	0.00035	0.00169	CcSEcCtD
Buprenorphine—Pain—Bleomycin—lymphatic system cancer	0.000349	0.00168	CcSEcCtD
Buprenorphine—Headache—Fludarabine—lymphatic system cancer	0.000348	0.00168	CcSEcCtD
Buprenorphine—Tachycardia—Carmustine—lymphatic system cancer	0.000347	0.00168	CcSEcCtD
Buprenorphine—Myalgia—Mitoxantrone—lymphatic system cancer	0.000345	0.00167	CcSEcCtD
Buprenorphine—Chest pain—Mitoxantrone—lymphatic system cancer	0.000345	0.00167	CcSEcCtD
Buprenorphine—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000345	0.00167	CcSEcCtD
Buprenorphine—Anxiety—Mitoxantrone—lymphatic system cancer	0.000344	0.00166	CcSEcCtD
Buprenorphine—Lethargy—Methotrexate—lymphatic system cancer	0.000342	0.00165	CcSEcCtD
Buprenorphine—Discomfort—Mitoxantrone—lymphatic system cancer	0.000341	0.00165	CcSEcCtD
Buprenorphine—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00034	0.00164	CcSEcCtD
Buprenorphine—Oedema—Vincristine—lymphatic system cancer	0.00034	0.00164	CcSEcCtD
Buprenorphine—Anorexia—Carmustine—lymphatic system cancer	0.000339	0.00164	CcSEcCtD
Buprenorphine—Infection—Vincristine—lymphatic system cancer	0.000337	0.00163	CcSEcCtD
Buprenorphine—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000336	0.00162	CcSEcCtD
Buprenorphine—Osteoarthritis—Methotrexate—lymphatic system cancer	0.000335	0.00162	CcSEcCtD
Buprenorphine—Confusional state—Mitoxantrone—lymphatic system cancer	0.000333	0.00161	CcSEcCtD
Buprenorphine—Nervous system disorder—Vincristine—lymphatic system cancer	0.000333	0.00161	CcSEcCtD
Buprenorphine—Hypotension—Carmustine—lymphatic system cancer	0.000332	0.0016	CcSEcCtD
Buprenorphine—Oedema—Mitoxantrone—lymphatic system cancer	0.000331	0.0016	CcSEcCtD
Buprenorphine—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000331	0.0016	CcSEcCtD
Buprenorphine—Nausea—Fludarabine—lymphatic system cancer	0.00033	0.00159	CcSEcCtD
Buprenorphine—Infection—Mitoxantrone—lymphatic system cancer	0.000329	0.00159	CcSEcCtD
Buprenorphine—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000328	0.00158	CcSEcCtD
Buprenorphine—Shock—Mitoxantrone—lymphatic system cancer	0.000325	0.00157	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000324	0.00156	CcSEcCtD
Buprenorphine—Urticaria—Bleomycin—lymphatic system cancer	0.000324	0.00156	CcSEcCtD
Buprenorphine—Anorexia—Vincristine—lymphatic system cancer	0.000324	0.00156	CcSEcCtD
Buprenorphine—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000323	0.00156	CcSEcCtD
Buprenorphine—Body temperature increased—Bleomycin—lymphatic system cancer	0.000322	0.00155	CcSEcCtD
Buprenorphine—Insomnia—Carmustine—lymphatic system cancer	0.000322	0.00155	CcSEcCtD
Buprenorphine—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000321	0.00155	CcSEcCtD
Buprenorphine—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00032	0.00154	CcSEcCtD
Buprenorphine—Paraesthesia—Carmustine—lymphatic system cancer	0.000319	0.00154	CcSEcCtD
Buprenorphine—Mood swings—Methotrexate—lymphatic system cancer	0.000318	0.00153	CcSEcCtD
Buprenorphine—Hypotension—Vincristine—lymphatic system cancer	0.000317	0.00153	CcSEcCtD
Buprenorphine—Dyspnoea—Carmustine—lymphatic system cancer	0.000317	0.00153	CcSEcCtD
Buprenorphine—Somnolence—Carmustine—lymphatic system cancer	0.000316	0.00153	CcSEcCtD
Buprenorphine—Anorexia—Mitoxantrone—lymphatic system cancer	0.000315	0.00152	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000309	0.00149	CcSEcCtD
Buprenorphine—Decreased appetite—Carmustine—lymphatic system cancer	0.000309	0.00149	CcSEcCtD
Buprenorphine—Hypotension—Mitoxantrone—lymphatic system cancer	0.000309	0.00149	CcSEcCtD
Buprenorphine—Insomnia—Vincristine—lymphatic system cancer	0.000307	0.00148	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000307	0.00148	CcSEcCtD
Buprenorphine—Paraesthesia—Vincristine—lymphatic system cancer	0.000305	0.00147	CcSEcCtD
Buprenorphine—Constipation—Carmustine—lymphatic system cancer	0.000304	0.00147	CcSEcCtD
Buprenorphine—Pain—Carmustine—lymphatic system cancer	0.000304	0.00147	CcSEcCtD
Buprenorphine—Breast disorder—Methotrexate—lymphatic system cancer	0.000303	0.00146	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000301	0.00145	CcSEcCtD
Buprenorphine—Hypersensitivity—Bleomycin—lymphatic system cancer	0.0003	0.00145	CcSEcCtD
Buprenorphine—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000297	0.00143	CcSEcCtD
Buprenorphine—Decreased appetite—Vincristine—lymphatic system cancer	0.000295	0.00142	CcSEcCtD
Buprenorphine—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000295	0.00142	CcSEcCtD
Buprenorphine—Somnolence—Mitoxantrone—lymphatic system cancer	0.000294	0.00142	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000293	0.00142	CcSEcCtD
Buprenorphine—Feeling abnormal—Carmustine—lymphatic system cancer	0.000293	0.00141	CcSEcCtD
Buprenorphine—Fatigue—Vincristine—lymphatic system cancer	0.000293	0.00141	CcSEcCtD
Buprenorphine—Asthenia—Bleomycin—lymphatic system cancer	0.000292	0.00141	CcSEcCtD
Buprenorphine—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000291	0.00141	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000291	0.0014	CcSEcCtD
Buprenorphine—Pain—Vincristine—lymphatic system cancer	0.00029	0.0014	CcSEcCtD
Buprenorphine—Constipation—Vincristine—lymphatic system cancer	0.00029	0.0014	CcSEcCtD
Buprenorphine—Asthma—Methotrexate—lymphatic system cancer	0.00029	0.0014	CcSEcCtD
Buprenorphine—Pruritus—Bleomycin—lymphatic system cancer	0.000288	0.00139	CcSEcCtD
Buprenorphine—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000288	0.00139	CcSEcCtD
Buprenorphine—Fatigue—Mitoxantrone—lymphatic system cancer	0.000285	0.00138	CcSEcCtD
Buprenorphine—Pain—Mitoxantrone—lymphatic system cancer	0.000283	0.00137	CcSEcCtD
Buprenorphine—Constipation—Mitoxantrone—lymphatic system cancer	0.000283	0.00137	CcSEcCtD
Buprenorphine—Abdominal pain—Carmustine—lymphatic system cancer	0.000281	0.00136	CcSEcCtD
Buprenorphine—Body temperature increased—Carmustine—lymphatic system cancer	0.000281	0.00136	CcSEcCtD
Buprenorphine—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.000278	0.00134	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000278	0.00134	CcSEcCtD
Buprenorphine—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000273	0.00132	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00027	0.00131	CcSEcCtD
Buprenorphine—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000269	0.0013	CcSEcCtD
Buprenorphine—Abdominal pain—Vincristine—lymphatic system cancer	0.000268	0.0013	CcSEcCtD
Buprenorphine—Body temperature increased—Vincristine—lymphatic system cancer	0.000268	0.0013	CcSEcCtD
Buprenorphine—Urticaria—Mitoxantrone—lymphatic system cancer	0.000263	0.00127	CcSEcCtD
Buprenorphine—Hypersensitivity—Carmustine—lymphatic system cancer	0.000262	0.00127	CcSEcCtD
Buprenorphine—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000261	0.00126	CcSEcCtD
Buprenorphine—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000261	0.00126	CcSEcCtD
Buprenorphine—Vomiting—Bleomycin—lymphatic system cancer	0.000259	0.00125	CcSEcCtD
Buprenorphine—Infestation NOS—Methotrexate—lymphatic system cancer	0.000258	0.00125	CcSEcCtD
Buprenorphine—Infestation—Methotrexate—lymphatic system cancer	0.000258	0.00125	CcSEcCtD
Buprenorphine—Depression—Methotrexate—lymphatic system cancer	0.000258	0.00124	CcSEcCtD
Buprenorphine—Rash—Bleomycin—lymphatic system cancer	0.000257	0.00124	CcSEcCtD
Buprenorphine—Dermatitis—Bleomycin—lymphatic system cancer	0.000257	0.00124	CcSEcCtD
Buprenorphine—Asthenia—Carmustine—lymphatic system cancer	0.000255	0.00123	CcSEcCtD
Buprenorphine—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000251	0.00121	CcSEcCtD
Buprenorphine—Hypersensitivity—Vincristine—lymphatic system cancer	0.00025	0.00121	CcSEcCtD
Buprenorphine—Sweating—Methotrexate—lymphatic system cancer	0.000248	0.0012	CcSEcCtD
Buprenorphine—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000244	0.00118	CcSEcCtD
Buprenorphine—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000244	0.00118	CcSEcCtD
Buprenorphine—Asthenia—Vincristine—lymphatic system cancer	0.000244	0.00118	CcSEcCtD
Buprenorphine—Diarrhoea—Carmustine—lymphatic system cancer	0.000243	0.00117	CcSEcCtD
Buprenorphine—Nausea—Bleomycin—lymphatic system cancer	0.000242	0.00117	CcSEcCtD
Buprenorphine—Asthenia—Mitoxantrone—lymphatic system cancer	0.000237	0.00115	CcSEcCtD
Buprenorphine—Dizziness—Carmustine—lymphatic system cancer	0.000235	0.00114	CcSEcCtD
Buprenorphine—Diarrhoea—Vincristine—lymphatic system cancer	0.000232	0.00112	CcSEcCtD
Buprenorphine—Pharyngitis—Methotrexate—lymphatic system cancer	0.00023	0.00111	CcSEcCtD
Buprenorphine—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000229	0.00111	CcSEcCtD
Buprenorphine—Urethral disorder—Methotrexate—lymphatic system cancer	0.000227	0.0011	CcSEcCtD
Buprenorphine—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000226	0.00109	CcSEcCtD
Buprenorphine—Vomiting—Carmustine—lymphatic system cancer	0.000226	0.00109	CcSEcCtD
Buprenorphine—Dizziness—Vincristine—lymphatic system cancer	0.000225	0.00108	CcSEcCtD
Buprenorphine—Rash—Carmustine—lymphatic system cancer	0.000224	0.00108	CcSEcCtD
Buprenorphine—Dermatitis—Carmustine—lymphatic system cancer	0.000224	0.00108	CcSEcCtD
Buprenorphine—Visual impairment—Methotrexate—lymphatic system cancer	0.000224	0.00108	CcSEcCtD
Buprenorphine—Headache—Carmustine—lymphatic system cancer	0.000223	0.00108	CcSEcCtD
Buprenorphine—Eye disorder—Methotrexate—lymphatic system cancer	0.000217	0.00105	CcSEcCtD
Buprenorphine—Tinnitus—Methotrexate—lymphatic system cancer	0.000216	0.00104	CcSEcCtD
Buprenorphine—Vomiting—Vincristine—lymphatic system cancer	0.000216	0.00104	CcSEcCtD
Buprenorphine—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000215	0.00104	CcSEcCtD
Buprenorphine—Rash—Vincristine—lymphatic system cancer	0.000214	0.00103	CcSEcCtD
Buprenorphine—Dermatitis—Vincristine—lymphatic system cancer	0.000214	0.00103	CcSEcCtD
Buprenorphine—Headache—Vincristine—lymphatic system cancer	0.000213	0.00103	CcSEcCtD
Buprenorphine—Nausea—Carmustine—lymphatic system cancer	0.000211	0.00102	CcSEcCtD
Buprenorphine—Angiopathy—Methotrexate—lymphatic system cancer	0.00021	0.00102	CcSEcCtD
Buprenorphine—Vomiting—Mitoxantrone—lymphatic system cancer	0.00021	0.00101	CcSEcCtD
Buprenorphine—Immune system disorder—Methotrexate—lymphatic system cancer	0.000209	0.00101	CcSEcCtD
Buprenorphine—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000209	0.00101	CcSEcCtD
Buprenorphine—Rash—Mitoxantrone—lymphatic system cancer	0.000209	0.00101	CcSEcCtD
Buprenorphine—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000208	0.00101	CcSEcCtD
Buprenorphine—Chills—Methotrexate—lymphatic system cancer	0.000208	0.001	CcSEcCtD
Buprenorphine—Headache—Mitoxantrone—lymphatic system cancer	0.000207	0.001	CcSEcCtD
Buprenorphine—Mental disorder—Methotrexate—lymphatic system cancer	0.000203	0.000981	CcSEcCtD
Buprenorphine—Erythema—Methotrexate—lymphatic system cancer	0.000202	0.000974	CcSEcCtD
Buprenorphine—Malnutrition—Methotrexate—lymphatic system cancer	0.000202	0.000974	CcSEcCtD
Buprenorphine—Nausea—Vincristine—lymphatic system cancer	0.000202	0.000974	CcSEcCtD
Buprenorphine—Dysgeusia—Methotrexate—lymphatic system cancer	0.000198	0.000954	CcSEcCtD
Buprenorphine—Nausea—Mitoxantrone—lymphatic system cancer	0.000196	0.000948	CcSEcCtD
Buprenorphine—Back pain—Methotrexate—lymphatic system cancer	0.000195	0.000943	CcSEcCtD
Buprenorphine—Vision blurred—Methotrexate—lymphatic system cancer	0.00019	0.000918	CcSEcCtD
Buprenorphine—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000187	0.000904	CcSEcCtD
Buprenorphine—Malaise—Methotrexate—lymphatic system cancer	0.000182	0.000879	CcSEcCtD
Buprenorphine—Vertigo—Methotrexate—lymphatic system cancer	0.000181	0.000876	CcSEcCtD
Buprenorphine—Cough—Methotrexate—lymphatic system cancer	0.000176	0.00085	CcSEcCtD
Buprenorphine—Convulsion—Methotrexate—lymphatic system cancer	0.000175	0.000844	CcSEcCtD
Buprenorphine—Arthralgia—Methotrexate—lymphatic system cancer	0.000172	0.00083	CcSEcCtD
Buprenorphine—Myalgia—Methotrexate—lymphatic system cancer	0.000172	0.00083	CcSEcCtD
Buprenorphine—Chest pain—Methotrexate—lymphatic system cancer	0.000172	0.00083	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000171	0.000824	CcSEcCtD
Buprenorphine—Discomfort—Methotrexate—lymphatic system cancer	0.00017	0.00082	CcSEcCtD
Buprenorphine—Confusional state—Methotrexate—lymphatic system cancer	0.000166	0.000802	CcSEcCtD
Buprenorphine—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000165	0.000795	CcSEcCtD
Buprenorphine—Infection—Methotrexate—lymphatic system cancer	0.000164	0.00079	CcSEcCtD
Buprenorphine—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000162	0.00078	CcSEcCtD
Buprenorphine—Skin disorder—Methotrexate—lymphatic system cancer	0.00016	0.000772	CcSEcCtD
Buprenorphine—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000159	0.000769	CcSEcCtD
Buprenorphine—Anorexia—Methotrexate—lymphatic system cancer	0.000157	0.000758	CcSEcCtD
Buprenorphine—Hypotension—Methotrexate—lymphatic system cancer	0.000154	0.000743	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.00015	0.000725	CcSEcCtD
Buprenorphine—Insomnia—Methotrexate—lymphatic system cancer	0.000149	0.000719	CcSEcCtD
Buprenorphine—Paraesthesia—Methotrexate—lymphatic system cancer	0.000148	0.000714	CcSEcCtD
Buprenorphine—Dyspnoea—Methotrexate—lymphatic system cancer	0.000147	0.000709	CcSEcCtD
Buprenorphine—Somnolence—Methotrexate—lymphatic system cancer	0.000146	0.000707	CcSEcCtD
Buprenorphine—Dyspepsia—Methotrexate—lymphatic system cancer	0.000145	0.0007	CcSEcCtD
Buprenorphine—Decreased appetite—Methotrexate—lymphatic system cancer	0.000143	0.000691	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000142	0.000687	CcSEcCtD
Buprenorphine—Fatigue—Methotrexate—lymphatic system cancer	0.000142	0.000686	CcSEcCtD
Buprenorphine—Pain—Methotrexate—lymphatic system cancer	0.000141	0.00068	CcSEcCtD
Buprenorphine—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000136	0.000655	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000135	0.00065	CcSEcCtD
Buprenorphine—Urticaria—Methotrexate—lymphatic system cancer	0.000131	0.000632	CcSEcCtD
Buprenorphine—Abdominal pain—Methotrexate—lymphatic system cancer	0.00013	0.000629	CcSEcCtD
Buprenorphine—Body temperature increased—Methotrexate—lymphatic system cancer	0.00013	0.000629	CcSEcCtD
Buprenorphine—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000121	0.000586	CcSEcCtD
Buprenorphine—Asthenia—Methotrexate—lymphatic system cancer	0.000118	0.000571	CcSEcCtD
Buprenorphine—Pruritus—Methotrexate—lymphatic system cancer	0.000117	0.000563	CcSEcCtD
Buprenorphine—Diarrhoea—Methotrexate—lymphatic system cancer	0.000113	0.000544	CcSEcCtD
Buprenorphine—Dizziness—Methotrexate—lymphatic system cancer	0.000109	0.000526	CcSEcCtD
Buprenorphine—Vomiting—Methotrexate—lymphatic system cancer	0.000105	0.000506	CcSEcCtD
Buprenorphine—Rash—Methotrexate—lymphatic system cancer	0.000104	0.000501	CcSEcCtD
Buprenorphine—Dermatitis—Methotrexate—lymphatic system cancer	0.000104	0.000501	CcSEcCtD
Buprenorphine—Headache—Methotrexate—lymphatic system cancer	0.000103	0.000498	CcSEcCtD
Buprenorphine—Nausea—Methotrexate—lymphatic system cancer	9.79e-05	0.000472	CcSEcCtD
